Generation Bio Co. (NASDAQ: GBIO)
$3.20
+0.2700 ( +9.21% ) 133.5K
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
Market Data
Open
$3.20
Previous close
$2.93
Volume
133.5K
Market cap
$212.23M
Day range
$2.87 - $3.25
52 week range
$0.86 - $5.69
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 14 | Jun 07, 2024 |
10-q | Quarterly Reports | 71 | May 13, 2024 |
8-k | 8K-related | 16 | May 13, 2024 |
ars | Annual reports | 1 | Apr 24, 2024 |
def | Proxies and info statements | 19 | Apr 24, 2024 |
4 | Insider transactions | 1 | Apr 17, 2024 |
4 | Insider transactions | 1 | Apr 17, 2024 |
4 | Insider transactions | 1 | Apr 17, 2024 |
4 | Insider transactions | 1 | Apr 17, 2024 |
4 | Insider transactions | 1 | Apr 17, 2024 |